Morbidity and mortality in schizophrenia with comorbid substance use disorders
Markku Lähteenvuo(University of Eastern Finland), Heidi Taipale(Niuvanniemi Hospital), Antti Tanskanen(University of Eastern Finland), Jurjen J. Luykx(Utrecht University), Jari Tiihonen(University of Eastern Finland), Ellenor Mittendorfer‐Rutz(Karolinska Institutet), Albert Batalla(Utrecht University)
Cited by 74
Related Papers
Suicide trends in the early months of the COVID-19 pandemic: an interrupted time-series analysis of preliminary data from 21 countries
|The Lancet Psychiatry|2021|742
Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
|World Psychiatry|2022|624
Mega-Analysis of Gray Matter Volume in Substance Dependence: General and Substance-Specific Regional Effects
|American Journal of Psychiatry|2018|272
Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema
|Circulation|2011|181